Bicara Therapeutics Inc. Common Stock Asset Resilience Ratio
Bicara Therapeutics Inc. Common Stock asset resilience ratio. Bicara Therapeutics Inc. Common Stock (BCAX) has an Asset Resilience Ratio of 78.22% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Bicara Therapeutics Inc. Common Stock (BCAX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bicara Therapeutics Inc. Common Stock (2024–2025)
Asset resilience ratio of Bicara Therapeutics Inc. Common Stock from 2024 to 2025. This chart shows how Bicara Therapeutics Inc. Common Stock's Asset Resilience Ratio has changed over time. Read debt load of Bicara Therapeutics Inc. Common Stock for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bicara Therapeutics Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BCAX total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $400.66 Million | 78.22% |
| Total Liquid Assets | $400.66 Million | 78.22% |
Asset Resilience Insights
- Very High Liquidity: Bicara Therapeutics Inc. Common Stock maintains exceptional liquid asset reserves at 78.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Bicara Therapeutics Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Bicara Therapeutics Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Bicara Therapeutics Inc. Common Stock Asset Resilience Ratio by Year (2024–2025)
Bicara Therapeutics Inc. Common Stock asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for Bicara Therapeutics Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.81% | $318.12 Million | $430.99 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $569.20 Million | -- |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was … Read more